tiprankstipranks
Alignment Healthcare (ALHC) Gets a Buy from Goldman Sachs
Blurbs

Alignment Healthcare (ALHC) Gets a Buy from Goldman Sachs

In a report released today, Nathan Rich from Goldman Sachs reiterated a Buy rating on Alignment Healthcare (ALHCResearch Report). The company’s shares opened today at $7.99.

According to TipRanks, Rich is a 4-star analyst with an average return of 6.5% and a 59.43% success rate. Rich covers the Healthcare sector, focusing on stocks such as Align Tech, Centene, and CVS Health.

Currently, the analyst consensus on Alignment Healthcare is a Moderate Buy with an average price target of $8.92.

See the top stocks recommended by analysts >>

Based on Alignment Healthcare’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $456.71 million and a GAAP net loss of $35.05 million. In comparison, last year the company earned a revenue of $360.35 million and had a GAAP net loss of $40.25 million

Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALHC in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alignment Healthcare (ALHC) Company Description:

Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which they receive healthcare coverage and services on an annual basis.

Read More on ALHC:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles